Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is a leading player in the regenerative biomaterial products and bioimplants market, with a strong focus on the wound-care, burn, surgical, sports medicine, and orthopedics markets. While the recent Medicare reimbursement reduction has caused some short-term headwinds for the company, MiMedx has a long-standing track record of success in the chronic wound care space and is actively diversifying its offerings to cover the surgical space as well. Additionally, management has taken steps to reduce operating expenses and streamline the corporate structure, which could lead to improved profitability in the future.

Bears say

MiMedx Group is facing several challenges, including low volume recovery in Wound Care Centers and Hospitals, a one-time restructuring charge, and a unique reimbursement situation that has impacted the stock. The company is also facing risks related to tissue donorship, competition in the 361 regulated products market, and its contracts with GPOs and IDNs. While the company has a strong track record and a best-in-class suite of clinical data, these challenges and risks may continue to weigh on the stock and impact its top-line growth. Additionally, the company's revenue streams from Advanced Surgical and international Wound Care are not impacted by recent updates, showing potential for growth in these areas. However, the company's ability to source enough tissue and scale its infrastructure may also impact its future business. Overall, these factors have led to a negative outlook on the company's stock.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.